CompletedNCT06064643
The Lived Experience of People With Von Willebrand Disease
Studying Von Willebrand disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Haemnet
- Principal Investigator
- Simon Fletcher, MA, MD, MPHHaemnet
- Intervention
- Online Survey(other)
- Enrollment
- 611 target
- Eligibility
- 16 years · All sexes
- Timeline
- 2023 – 2025
Study locations (1)
- Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, United Kingdom
Collaborators
Hemab ApS
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06064643 on ClinicalTrials.govOther trials for Von Willebrand disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07404644An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)Takeda
- RECRUITINGPHASE3NCT07115004Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)Vega Therapeutics, Inc
- RECRUITINGPHASE3NCT07129343A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)Takeda
- RECRUITINGPHASE3NCT06998524A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand DiseaseHoffmann-La Roche
- RECRUITINGNCT06883240An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care TreatmentHoffmann-La Roche
- RECRUITINGPHASE3NCT05582993A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)Takeda
- RECRUITINGPHASE3NCT06205095A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients with VWDUnity Health Toronto
- RECRUITINGPHASE1, PHASE2NCT05776069Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)Vega Therapeutics, Inc